Red blood cell nanosponge - Cellics Therapeutics
Alternative Names: RBC-NSLatest Information Update: 28 Aug 2023
At a glance
- Originator Cellics Therapeutics
- Class Antianaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune haemolytic anaemia
Most Recent Events
- 03 Jul 2023 Red blood cell nanosponge - Cellics Therapeutics is available for licensing as of 03 Jul 2023. https://www.cellics.com/about/
- 03 Jul 2023 Preclinical trials in Autoimmune haemolytic anaemia in USA (unspecified route) (Cellics Therapeutics pipeline, July 2023)
- 07 Sep 2021 Cellics Therapeutics has patent protection for Red blood cell nanosponge in USA